Skip to main content
Novel hereditary ATTR amyloidosis genetic testing program launched
6/13/2018

Ambry Genetics and collaborator Akcea Therapeutics have launched hATTR Compass, a novel genetic testing program that will help people with suspected hereditary transthyretin amyloidosis through free, confidential analyses and genetic counseling. Ambry will provide testing services for people age 18 and older living in the US or Canada; the mobile app Backpack Health will allow for symptom tracking; and confidential genetic counseling will be provided through program partner PWNHealth, a virtual care company.

Full Story: